KD Pharma adds to omega-3 API production supply chain with UK site

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dutko)
(Image: Getty/dutko)

Related tags: API, Supply chain, Manufacturing, Production line, Omega-3 fatty acid, Pharmaceutical companies

KD Pharma adds manufacturing site in Seal Sands, UK, to manufacture omega-3-based intermediates for use in API production.

With seven sites across Europe and the US, KD Pharma aims to add on to the growing omega-3 active pharmaceutical ingredient (API) market. The company produces omega-3 products for the use in finished products, such as soft gel capsules and bottled liquid forms of pharmaceutical products.

With the acquisition of the UK manufacturing site, KD Pharma will be able to meet the market demand for supplying the omega-3 APIs for product approvals, label expansions, and clinical research of drug candidates.

Oscar Groet, CEO of KD Pharma, said in a statement that this site acquisition will expand the company’s technology and manufacturing base for producing API’s that have the highest concentrations of EPA and DHA omega-3s.

The Seal Sands site, which was previously used for the manufacturing of omega-3 products, will be brought online for intermediate production later this year.

Related news

Related products

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us


View more